We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Seegene

  Gold Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Showcases New STARlet-AIOS All-in-One Solution for All Molecular Testing at MEDLAB Middle East

By LabMedica International staff writers
Posted on 25 Jan 2022
Print article
Image: STARlet-AIOS (Photo courtesy of Seegene, Inc.)
Image: STARlet-AIOS (Photo courtesy of Seegene, Inc.)

Seegene, Inc. (Seoul, Korea) presented its recently launched STARlet-AIOS All-in-One Solution for All Molecular Testing at MEDLAB Middle East which took place 24-27 January 2022 at the Dubai World Trade Centre.

Seegene’s new STARlet-AIOS is a unique modular configuration that integrates existing standalone instruments, enabling easy installation, upgrade and maintenance. Combined with Seegene's proprietary high-multiplex real-time PCR reagent technology, Seegene STARlet-AIOS provides an ultimate solution that could perform various syndromic tests with one system. The STARlet-AIOS is the world's one and only modular concept that enables a fully automated workflow while maintaining the standalone instruments, STARlet and CFX96 Dx. It no longer requires a large installation space and provides convenience in maintenance and repair.

What sets Seegene STARlet-AIOS apart is its unique high multiplex Real-Time PCR reagent technology. Within the same disease group such as respiratory, GI, or STI, Seegene’s syndromic test can find the exact cause of a specific symptom with a single test. Seegene’s currently available products can be applied on the STARlet-AIOS and its newly developed products will also be compatible with the solution, thus further increasing its expandability. With the all-in-one solution, diverse syndromic tests can be carried out with a single system, optimizing the testing environment.

From sample input to data analysis, Seegene STARlet-AIOS provides a streamlined process for molecular testing. The entire workflow is fully automated with Seegene’s solution. Just a click of a button is all that is needed. An inserted sample plate goes through the extraction, followed by the PCR setup process within the extraction instrument STARlet. Once the extraction and PCR setup are finished, the sample plate is moved down to the lower level by the elevator robot. The plate is then picked up by the plate handler robot and moved to the plate sealer for automated sealing process. Once the sealing is done, the plate is again picked up by the plate handler robot and put into the CFX96 for Real-Time PCR. After the PCR, Seegene’s seamless software solution provides not only accurate quantitative test results but also customized statistical analysis in an easy to see visualized format with insights.

By completely eliminating the manual process, the possibility of human error and contamination is minimized throughout the entire testing process. As a result, the medical staff can obtain accurate test results by working in a safe and efficient environment. Seegene STARlet-AIOS is a compact yet complete testing solution that generates same-day results even with small sample sizes, making it perfect for clinics and labs of all sizes.

Related Links:
Seegene, Inc. 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Benchtop Real-Time PCR Analyzer
Savanna
New
High-Throughput Cellular Screening System
FLIPR Penta
New
Semi-Auto Urine Test Strip Analyzer
HTI CL-50 Plus

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.